MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) is a clinical research site located in Houston, Texas, United States 77030.
Crixeo Health Trust Score: 69/100 (FAIR). This profile has not yet been claimed by the site owner.
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) has participated in 7 clinical trials.
Therapeutic areas: Tumor Pathway Activations Inhibited by Dovitinib, PTCH1 or SMO Activated Solid and Hematologic Tumors, Tumors With Aberrations in ALK or ROS1.
Sponsors: Novartis Pharmaceuticals, Pfizer.
Trust Score: 69/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) has a Crixeo Trust Score of 69/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) has 7 clinical trials on record. Their work covers Tumor Pathway Activations Inhibited by Dovitinib, PTCH1 or SMO Activated Solid and Hematologic Tumors, Tumors With Aberrations in ALK or ROS1.
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.